Equol and Vascular Function in Women With Chronic Kidney Disease

Part of paid clinical trials in Aurora, Colorado.

Sponsor
University of Colorado, Denver
Study ID
NCT07194590
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Blood Pressure
  • Cerebrovascular Function
  • Chronic Kidney Disease (Stage 3-4)
  • Cognitive Functions
  • Vascular Function

Eligibility Criteria

Sex
FEMALE
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Equol — DRUG
    This group will receive 10 mg equol per day (2 capsules/day, 5mg equol/capsule).
  • Placebo — DRUG
    This group will receive 2 placebo capsules per day.

Study Details

The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the effect of 12 weeks of oral equol supplementation on vascular function in postmenopausal women with CKD.

Key Dates

Start date
Feb 19, 2026
Status verified
Sep 2025
Primary completion
Nov 30, 2030
Completion
Nov 30, 2030

Study Design

Enrollment
74 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Equol
    This group will receive 10 mg equol per day (2 capsules/day, 5mg equol/capsule).
  • Placebo Comparator: Placebo
    This group will receive 2 placebo capsules per day.

Primary Outcome Measure

Brachial Artery Flow-Mediated Dilation (FMDBA) [ Time Frame: Baseline, 12 weeksv ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Colorado Anschutz Medical CampusAuroraColorado80045
Emily Andrews
[email protected]
303-724-2275

Find similar trials in Aurora, CO

By research site
University of Colorado Anschutz Medical Campus· Aurora, CO

Related Studies